Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 226

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Open access
Mercer, Louise K, Lunt, Mark, Low, Audrey L S, Dixon, William G, Watson, Kath D, Symmons, Deborah P M, Hyrich, Kimme L, Maiden, Nicola, Price, Tom, Hopkinson, Neil, O'Reilly, Sheila, Hordon, Lesley, Griffiths, Ian, Porter, Duncan, Madhok, R, Hassell, Andy, Cooper, R G, Choy, Ernest, Walsh, David, Emery, Paul, Knight, Susan, Bruce, Ian, Taggart, Allister, Scott, David, Thompson, Paul, McCrae, Fiona, Goodfellow, Rhian, Kitas, George, Jubb, Ronald, Abernethy, Rikki, Green, Sandra, Sanders, Paul, Coulson, Amanda, Harrison, Bev, Bukhari, Marwan, Klimiuk, Peter · 2015 · Annals of the Rheumatic Diseases

Abstract

BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased risk of certain solid cancers, in particular lung cancer, compared to the general population. Treatment with tumour necrosis factor (TNF) inhibitors (TNFi) may further enhance this risk. OBJECTIVES: To compare the risk of solid cancer in patients with RA treated with TNFi to that in patients treated with non-biologic (synthetic) disease modifying antirheumatic drugs (sDMARDs). METHODS: Patients with a physician diagnosis of RA enrolled in the British Society for Rheumatology Biologics Register, a national prospective cohort study established in 2001 to monitor the long-term safety of TNFi, were followed via record linkage with the national cancer registries until first solid cancer, death, for 5 years, or until 2011. Rates of solid cancers in 11 767 patients without prior cancer who received TNFi were compared to those in 3249 patients without prior cancer treated with sDMARDs. RESULTS: 427 solid cancers were reported in 52 549 patient-years follow-up for the TNFi group (81 (95% CI 74 to 89) per 10 000 patient-years) and 136 cancers were reported in 11 672 patient-years in the sDMARD cohort (117 (95% CI 98 to 138) per 10 000 patient-years). After adjusting for differences in baseline characteristics there was no difference in risk of solid cancer for TNFi compared to sDMARD treated patients: HR 0.83 (95% CI 0.64 to 1.07). There was no difference in the relative risk of cancer for any of the individual TNFi drugs. CONCLUSIONS: The addition of TNFi to sDMARD does not alter the risk of cancer in RA patients selected for TNFi in the UK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2013-204851

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 226

Metadata

Authors
Mercer, L. K., Lunt, M., Low, A. L. S., Dixon, W. G., Watson, K. D., Symmons, D. P. M., Hyrich, K. L., Maiden, N., Price, T., Hopkinson, N., O'Reilly, S., Hordon, L., Griffiths, I., Porter, D., Madhok, R., Hassell, A., Cooper, R. G., Choy, E., Walsh, D., Emery, P., Knight, S., Bruce, I., Taggart, A., Scott, D., Thompson, P., McCrae, F., Goodfellow, R., Kitas, G., Jubb, R., Abernethy, R., Green, S., Sanders, P., Coulson, A., Harrison, B., Bukhari, M., & Klimiuk, P.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2015-06
Volume
74
Issue
6
Pages
1087-1093
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2149521567
Cited by
226
References
3
FWCI
17.16
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. https://app.cochat.ai/papers/10.1136/annrheumdis-2013-204851
The paper
Mercer, L. K., Lunt, M., Low, A. L. S., Dixon, W. G., Watson, K. D., Symmons, D. P. M., Hyrich, K. L., Maiden, N., Price, T., Hopkinson, N., O'Reilly, S., Hordon, L., Griffiths, I., Porter, D., Madhok, R., Hassell, A., Cooper, R. G., Choy, E., Walsh, D., . . . Klimiuk, P. (2015). Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2013-204851

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.